Unified Patent Court – one step closer to opening the Court

In Insights, Uncategorized

26 October, 2015

On October 1 2015, a Protocol to the UPC Agreement was signed by first seven member states [1]. It is open for signing by the remaining Signatory States of the UPC Agreement from this date.
The aim of the Protocol is to allow for some provisions of the UPC Agreement to be applied early, i.e. before the Court opens, in a provisional application phase. The Protocol will enter into force the day after 13 Signatory states (including Germany, France and the UK) have ratified the UPC Agreement.

This provisional application phase will allow for the recruitment of judges and testing of the IT system. Having judges appointed and trained at the date the Court opens is important, as it is conceivable that the Court could receive cases essentially on the first day the Agreement comes into effect.

Further to this, the protocol also allows for the Registry to be operational, which would possibly allow for patent holders to file their opt-out requests for European patents and also Supplementary Protection Certificates (SPC) before the Court opens, during a so called “sunrise period”.

The articles that would come into effect before the Agreement are thus mainly of an institutional character, Article 1-2, 4-5, 6(1), 7, 10-19, 35(1, 3 and 4), 36-41 and 71(3) of the Agreement on a Unified Patent Court and Article 1-7(1), 7(5), 9-18, 20(1), 22-28, 30, 32 and 33 of the Statute of the Unified Patent Court. Article 1 is related to Establishing the Unified Patent Court. Articles 15-19 are related to the appointment of Judges and Article 10 is related to the Registry [2].

Sofia Willquist, European Patent Attorney

You may also be interested in:

Companies with IP generate at least 23.8% more revenue according to latest EU report

The report ‘The Intellectual Property Rights and Firm Performance in the European Union’ was published last month and analyses

Read more...

European Commission reports show misuse of divisionals can in itself contravene EU law

In November last year, I was interviewed about the European Commission’s €462.6 million fine against pharmaceutical giant Teva and

Read more...

IP Enforcement Strategies: Combating Counterfeiting in Southeast Asia and China

Counterfeiting remains among the most significant threats to intellectual property rights globally, particularly in Southeast Asia and China. These

Read more...

Mobile Sliding Menu